Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tsubota Laboratory Incorporated ( (JP:4890) ) has provided an announcement.
Tsubota Laboratory Incorporated has announced its interim financial results for the fiscal year ending March 31, 2026, emphasizing its commitment to sustainable growth. The company is dedicated to leveraging scientific evidence to create innovative healthcare solutions, which could enhance its market position and provide significant social and economic value. This approach underscores Tsubota Lab’s unique management philosophy, aiming to balance commercial success with addressing critical social health issues.
The most recent analyst rating on (JP:4890) stock is a Hold with a Yen363.00 price target. To see the full list of analyst forecasts on Tsubota Laboratory Incorporated stock, see the JP:4890 Stock Forecast page.
More about Tsubota Laboratory Incorporated
Tsubota Laboratory Incorporated is an R&D-type venture company originating from the School of Medicine at Keio University. The company focuses on creating innovative solutions for myopia, dry eye, presbyopia, and brain diseases, aiming to address social issues related to visual function and brain health. Their core value, ‘VISIONary INNOVATION,’ combines deep insight into visual diseases with foresight and innovation to develop future-oriented medical and healthcare products.
Average Trading Volume: 37,019
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.87B
Find detailed analytics on 4890 stock on TipRanks’ Stock Analysis page.